News Medical on MSN2d
Combination therapy shows promising results in treating stage 3 melanoma
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...
2minutemedicine.com5d
Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors
No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib ...
Novel immunotherapy combo shows promise in melanoma
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...
Too Old to Operate18d
In Advanced RCC, Rechallenging Patients With ICIs May Not Be Beneficial, but Tivozanib Monotherapy Shows Promise Post-ICI
Rechallenging patients with ICIs may not be beneficial in advanced RCC, but Tivozanib monotherapy shows promise as an ...
New Drug Therapy Cuts Death Risk From Advanced Blood Cancer By Half; Here's How
Adding the drug nivolumab to AVD therapy halves the rate of cancer progression or death for blood cancer patients, compared ...
Too Old to Operate10d
Perioperative Chemotherapy & Nivolumab Provide Safe, Long-Term Benefits for Patients With Resectable Stage IIIA NSCLC
The following is a summary of “Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year ...
Targeted Oncology13d
Opinions on Treatment Split for Prominent Questions in Bladder Cancer
Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a ...
The New England Journal of Medicine20d
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
Patients were randomly assigned to receive brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (BV+AVD) or nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD).
EurekAlert!20d
Nature Communications: Nivolumab and anlotinib show promising results in advanced stomach cancer
Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...
MedPage Today20d
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of ...
New Zealanders Can Now Access Funded OPDIVO® (Nivolumab) For Previously Treated Metastatic Renal Cell Carcinoma
Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...